Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study.
Publication
, Conference
Owonikoko, TK; Kim, HR; Govindan, R; Ready, N; Reck, M; Peters, S; Dakhil, SR; Navarro, A; Rodriguez-Cid, J; Schenker, M; Lee, JS; Percent, I ...
Published in: Ann Oncol
April 2019
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Ann Oncol
DOI
EISSN
1569-8041
Publication Date
April 2019
Volume
30 Suppl 2
Start / End Page
ii77
Location
England
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Owonikoko, T. K., Kim, H. R., Govindan, R., Ready, N., Reck, M., Peters, S., … Park, K. (2019). Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study. In Ann Oncol (Vol. 30 Suppl 2, p. ii77). England. https://doi.org/10.1093/annonc/mdz094
Owonikoko, T. K., H. R. Kim, R. Govindan, N. Ready, M. Reck, S. Peters, S. R. Dakhil, et al. “Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study.” In Ann Oncol, 30 Suppl 2:ii77, 2019. https://doi.org/10.1093/annonc/mdz094.
Owonikoko TK, Kim HR, Govindan R, Ready N, Reck M, Peters S, et al. Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study. In: Ann Oncol. 2019. p. ii77.
Owonikoko, T. K., et al. “Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study.” Ann Oncol, vol. 30 Suppl 2, 2019, p. ii77. Pubmed, doi:10.1093/annonc/mdz094.
Owonikoko TK, Kim HR, Govindan R, Ready N, Reck M, Peters S, Dakhil SR, Navarro A, Rodriguez-Cid J, Schenker M, Lee JS, Gutierrez V, Percent I, Morgensztern D, Fairchild J, Baudelet C, Park K. Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study. Ann Oncol. 2019. p. ii77.
Published In
Ann Oncol
DOI
EISSN
1569-8041
Publication Date
April 2019
Volume
30 Suppl 2
Start / End Page
ii77
Location
England
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis